VAP-1 Antibody (A-8): sc-166713

VAP-1 Antibody (A-8) is a mouse monoclonal IgG2a kappa light chain antibody that detects VAP-1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). VAP-1 Antibody (A-8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VAP-1, also known as vascular adhesion protein-1, plays a crucial role in immune response by facilitating lymphocyte adhesion to vascular endothelium, essential for immune cell migration from bloodstream to lymphoid tissues and inflammation sites. VAP-1 is a type II transmembrane sialoglycoprotein predominantly expressed on endothelial cells during inflammatory conditions, with significantly upregulated expression. VAP-1 functions as both an adhesion molecule and a monoamine oxidase enzyme, important for biogenic amine metabolism. VAP-1′s structure includes a single transmembrane domain and multiple glycosylation sites, critical for function and stability. VAP-1 predominantly exists as a homodimer, requiring proper glycosylation for mediating lymphocyte adhesion and recirculation. VAP-1 is expressed in various smooth muscle cells, though not supporting lymphocyte binding in these cells. Soluble VAP-1 levels are elevated in patients with inflammatory liver diseases, suggesting potential use as a biomarker.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VAP-1 Antibody (A-8) References:

1. Human vascular adhesion protein-1 (VAP-1) plays a critical role in lymphocyte-endothelial cell adhesion cascade under shear.  |  Salmi, M., et al. 2000. Circ Res. 86: 1245-51. PMID: 10864915
2. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo.  |  Tohka, S., et al. 2001. FASEB J. 15: 373-82. PMID: 11156953
3. Human vascular adhesion proteın-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease.  |  Kemik, O., et al. 2010. World J Surg Oncol. 8: 83. PMID: 20849600
4. VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients.  |  Koc-Zorawska, E., et al. 2012. Kidney Blood Press Res. 36: 242-7. PMID: 23154672
5. Therapeutic advantage of anti-VAP-1 over anti-α4 integrin antibody in concanavalin a-induced hepatitis.  |  Lee, WY., et al. 2013. Hepatology. 58: 1413-23. PMID: 23686782
6. Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.  |  Sun, P., et al. 2014. Cerebrovasc Dis. 37: 171-80. PMID: 24503888
7. Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control.  |  Sun, P., et al. 2018. Biochim Biophys Acta Mol Basis Dis. 1864: 542-553. PMID: 29175057
8. Human vascular adhesion protein 1 (VAP-1) is a unique sialoglycoprotein that mediates carbohydrate-dependent binding of lymphocytes to endothelial cells.  |  Salmi, M. and Jalkanen, S. 1996. J Exp Med. 183: 569-79. PMID: 8627168
9. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule.  |  Smith, DJ., et al. 1998. J Exp Med. 188: 17-27. PMID: 9653080
10. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.  |  Kurkijärvi, R., et al. 1998. J Immunol. 161: 1549-57. PMID: 9686623
11. Structural model of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1) D4 domain is an amine oxidase.  |  Salminen, TA., et al. 1998. Protein Eng. 11: 1195-204. PMID: 9930668

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VAP-1 Antibody (A-8) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-VAP-1 Antibody (A-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VAP-1 Antibody (A-8) Specifications

Alternate Product Name: VAP-1

Product Clone Name: A-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 749-763

Epitope Target: VAP-1

Epitope Species: human

Product Reactivity/Detection: VAP-1 and placenta copper monamine oxidase

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: canine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for VAP-1 Antibody (A-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin